Daiichi Sankyo Korea, Daewoong to co-promote hypertensive agent in combination form

Published: 2009-06-12 06:57:00

Updated: 2009-06-12 06:57:00

Daiichi Sankyo Korea has joined hands with Daewoong Pharm to market Sevicar, a combination of the angiotensin II receptor antagonist olmesartan, and the calcium channel blocker amlodipine) from July 10.

Sevicar is a convenient, once daily, single tablet combination of amlodipine, the most pres...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK